<http://schema.org/articleBody>
"<p>\n\tDynavax Technologies Corporation has enrolled over 500 patients in a late-stage test of the hepatitis B vaccine called Heplisav for people with chronic kidney disease in 69 different locations in Germany, Canada and the United States.<br />\n\t<br />\n\tPatients will be immunized three times over the course of six months, BizJournals.com reports. The primary endpoint effectiveness for the Phase III trial is expected be studied at seven months. The hope is that Heplisav is classified as &quot;non-inferior&quot; to GlaxoSmithLine&#39;s Enegerix-B vaccine.<br />\n\t<br />\n\tDynavax has conducted nine clinical trials over the past decade, which have involved close to 2,500 individuals. The company hopes to target unmet medical needs of end-stage renal disease patients and adults by providing higher protection with fewer doses.<br />\n\t<br />\n\tThe vaccine is based on proprietary immunostimulatory sequences that target&nbsp; the Toll-like Receptor 9 in an effort to stimulate an innate immune response.<br />\n\t<br />\n\tHepislav combines a hepatitis B surface antigen with the first generation 1018 ISS.<br />\n\t<br />\n\tTwo Investigational New Drug Applications for Hepislav are currently on U.S. FDA clinical hold.<br />\n\t<br />\n\tThe final immunizations for the current trial will be given in June.<br />\n\t<br />\n\tHepatitis B is a chronic disease that may lead to hepatocellular carcinoma and cirrhosis of the liver. While there is no cure for hepatitis B, disease prevention through effective vaccines can limit its spread.</p>\n"^^<http://www.w3.org/2001/XMLSchema#string>
<http://vaccinenewsdaily.com/stories/510531612-dynavax-begins-late-stage-hepatitis-b-vaccine-test>